Global Blood Therapeutics Inc. (GBT)

51.90
0.74 1.45
NASDAQ : Health Technology
Prev Close 51.16
Open 50.63
Day Low/High 50.19 / 52.57
52 Wk Low/High 30.15 / 64.94
Volume 709.76K
Avg Volume 776.50K
Exchange NASDAQ
Shares Outstanding 60.23M
Market Cap 2.94B
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

GUERBET : 2016 Revenue

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Fear of Missing Out Is Building

Fear of Missing Out Is Building

You can feel the misery of those who are struggling with feelings of being left behind.

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

7 Low-Priced Stocks to Watch in 2017

7 Low-Priced Stocks to Watch in 2017

Good picks make it easier to produce good results, but they are just a starting point.

Shark Bites: We Knew Today Would Be Slow, but Come On…

Shark Bites: We Knew Today Would Be Slow, but Come On…

Don't force it; there's no energy.

Interesting GBT Put And Call Options For January 2017

Interesting GBT Put And Call Options For January 2017

Investors in Global Blood Therapeutics Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.

Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug

Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug

Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.

GUERBET : 3rd Quarter 2016 Revenue

GUERBET : 3rd Quarter 2016 Revenue

Global Blood Therapeutics Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease

Global Blood Therapeutics Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease

Data Presented at 10th Anniversary Conference of Academy for Sickle Cell and Thalassemia (ASCAT)

Shark Bites: Two Big Movers

Shark Bites: Two Big Movers

'If there are worries about the market topping out it isn't evident in [today's] price action.'